Last reviewed · How we verify
10% phenylephrine
At a glance
| Generic name | 10% phenylephrine |
|---|---|
| Also known as | Phenylephrine 10%, Pupil Dilation |
| Sponsor | Denver Health and Hospital Authority |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive (PHASE1)
- Minimum Effective Volume of Crystalloid Co-Loading to Prevent Spinal Anesthesia-Induced Hypotension in Cesarean Section (NA)
- Autoimmune Basis for Postural Tachycardia Syndrome (NA)
- Use of Phenylephrine for Assessment of Mitral Regurgitation Severity (PHASE1, PHASE2)
- Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes (PHASE4)
- Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects (PHASE1)
- Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity (EARLY_PHASE1)
- Retinal Vascular Changes in Patients After Coronavirus Disease 2019 (COVID-19)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 10% phenylephrine CI brief — competitive landscape report
- 10% phenylephrine updates RSS · CI watch RSS
- Denver Health and Hospital Authority portfolio CI